The FDA has approved the oral Janus kinase (JAK) inhibitor deuruxolitinib ( Leqselvi – Sun) for treatment of severe alopecia areata in adults. Two other oral JAK inhibitors are approved for treatment of…
Med Lett Drugs Ther. 2025 Oct 27; 67(1740):174-6 doi:10.58347/tml.2025.1740b
The FDA has approved the oral Janus kinase (JAK) inhibitor deuruxolitinib ( Leqselvi – Sun) for treatment of severe alopecia areata in adults. Two other oral JAK inhibitors are approved for treatment of severe alopecia areata: baricitinib (Olumiant) is approved for use in adults, and ritlecitinib (Litfulo) is approved for use in patients ≥12 years old.
The FDA has approved ritlecitinib ( Litfulo – Pfizer), an oral JAK and TEC kinase family inhibitor, for treatment of severe alopecia areata in patients ≥12 years old. Ritlecitinib is the second oral drug…
Med Lett Drugs Ther. 2023 Nov 27; 65(1690):185-6 doi:10.58347/tml.2023.1690a
The FDA has approved ritlecitinib ( Litfulo – Pfizer), an oral JAK and TEC kinase family inhibitor, for treatment of severe alopecia areata in patients ≥12 years old. Ritlecitinib is the second oral drug to be approved in the US for treatment of severe alopecia areata; baricitinib (Olumiant) , a JAK inhibitor, is approved only for use in adults.
Topical minoxidil ( Rogaine , and others), which is available over the counter, has been used for treatment of hair loss in men and women for more than 30 years. Recently published trials suggest that…
Med Lett Drugs Ther. 2022 Dec 26; 64(1666):208
Topical minoxidil ( Rogaine , and others), which is available over the counter, has been used for treatment of hair loss in men and women for more than 30 years. Recently published trials suggest that off-label use of a low dose of oral minoxidil may also be effective.
The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly), which was previously approved by the FDA for treatment of moderately to severely active rheumatoid arthritis and treatment of COVID-19…
Med Lett Drugs Ther. 2022 Sep 5; 64(1658):139-41
The oral Janus kinase (JAK) inhibitor baricitinib ( Olumiant – Lilly), which was previously approved by the FDA for treatment of moderately to severely active rheumatoid arthritis and treatment of COVID-19 in certain hospitalized adults, has now been approved for treatment of severe alopecia areata in adults. Baricitinib is the first systemic treatment to be approved in the US for this indication.
The FDA has approved the prostaglandin analog bimatoprost in a 0.03% solution (Latisse - Allergan ) for increasing eyelash length, thickness and darkness in patients with hypotrichosis of the eyelashes.
Med Lett Drugs Ther. 2009 Jun 1; 51(1313):43-4
The FDA has approved the prostaglandin analog bimatoprost in a 0.03% solution (Latisse - Allergan ) for increasing eyelash length, thickness and darkness in patients with hypotrichosis of the eyelashes.
Finasteride and minoxidil continue to be the only drugs approved by the FDA to treat alopecia. Since these agents have different mechanisms of action, some clinicians have used both to treat hair loss in men.
Med Lett Drugs Ther. 2005 Nov 21; 47(1222):95-6
Finasteride and minoxidil continue to be the only drugs approved by the FDA to treat alopecia. Since these agents have different mechanisms of action, some clinicians have used both to treat hair loss in men.
Two new formulations of existing drugs were recently approved by the FDA for treatment of male androgenetic alopecia. Finasteride, a steroid 5alpha-reductase inhibitor previously marketed in a 5-mg tablet as…
Med Lett Drugs Ther. 1998 Feb 27; 40(1021):25-7
Two new formulations of existing drugs were recently approved by the FDA for treatment of male androgenetic alopecia. Finasteride, a steroid 5alpha-reductase inhibitor previously marketed in a 5-mg tablet as Proscar for treatment of benign prostatic hyperplasia (Medical Letter, 34:83, 1992), has now been approved in a 1-mg tablet as Propecia (Merck) for oral treatment of men with male pattern hair loss. Minoxidil, a peripheral vasodilator used to treat hypertension, was previously available over the counter in a 2% topical solution ( Rogaine , and others) for treatment of androgenetic alopecia in men or women (Medical Letter, 36:9, 1994); it has now also been marketed in a 5% topical solution ( Rogaine Extra Strength for Men - Pharmacia & Upjohn) for over-the-counter use in men only.
Minoxidil 2% topical solution ( Rogaine - Upjohn) has been available in the USA since 1988 for treatment of androgenetic alopecia (Medical Letter, 29:87, 1987). Although available only by prescription, it is…
Med Lett Drugs Ther. 1994 Jan 21; 36(914):9-10
Minoxidil 2% topical solution ( Rogaine - Upjohn) has been available in the USA since 1988 for treatment of androgenetic alopecia (Medical Letter, 29:87, 1987). Although available only by prescription, it is advertised on television to the general public.